# Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis

> **NCT01320579** · PHASE2 · COMPLETED · sponsor: **BioCis Pharma Ltd** · enrollment: 159 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Cis-UCA 2.5% emulsion cream
- **DRUG:** Cis-UCA 5% emulsion cream
- **DRUG:** Placebo for cis-UCA emulsion cream
- **DRUG:** Protopic® 0.1% ointment

## Key facts

- **NCT ID:** NCT01320579
- **Lead sponsor:** BioCis Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2012-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320579, "Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01320579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*